Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Alfred Nobels Allé, 8, 141 52, Stockholm, Sweden.
Mabtech AB, Box 1233, 131 28, Nacka Strand, Sweden.
Calcif Tissue Int. 2020 Feb;106(2):194-207. doi: 10.1007/s00223-019-00618-w. Epub 2019 Oct 25.
Tartrate-resistant acid phosphatase type 5 (TRAP) exists as two isoforms, 5a and 5b. 5b is a marker of osteoclast number and 5a of chronic inflammation; however, its association with bone resorption is unknown. In this study, a double-TRAP 5a/5b sandwich ELISA measuring 5a and 5b protein in the same sample was developed. TRAP 5a and 5b protein levels were evaluated as osteoclast differentiation/activity markers in serum and in culture, and their correlation to the resorption marker CTX-I was examined. Serum TRAP 5a and 5b concentrations in healthy men were 4.4 ± 0.6 ng/ml and 1.3 ± 0.2 ng/ml, respectively, and they correlated moderately to each other suggesting that their secretion is coupled under healthy conditions. A correlation was also observed between serum TRAP 5a and 5b with CTX-I, suggesting that both TRAP isoforms associate with osteoclast number. During osteoclast differentiation on plastic/bone, predominantly 5b increased in media/lysate from M-CSF/RANKL-stimulated CD14+ PBMCs. However, substantial levels of 5a were detected at later stages suggesting that both isoforms are secreted from differentiating OCs. More TRAP 5b was released on bone indicating a connection to osteoclast resorptive activity, and a peak in TRAP 5b/5a-ratio coincided with rapid CTX-I release. At the end of the culture period of M-CSF + RANKL-stimulated CD14+ PBMCs, there was a correlation between the secretion of TRAP 5a and 5b proteins with CTX-I. The correlation of not only 5b but also 5a with collagen degradation, both in serum and osteoclast cultures indicates that a considerable proportion of the TRAP 5a originates from osteoclasts and may reflect a hitherto undisclosed regulatory mechanism during bone resorption and bone remodeling.
抗酒石酸酸性磷酸酶 5 型(TRAP)存在两种同工酶,5a 和 5b。5b 是破骨细胞数量的标志物,5a 是慢性炎症的标志物;然而,其与骨吸收的关系尚不清楚。在本研究中,开发了一种双重 TRAP 5a/5b 夹心 ELISA,可在同一样本中测量 5a 和 5b 蛋白。评估了血清和培养物中 TRAP 5a 和 5b 蛋白作为破骨细胞分化/活性标志物的水平,并检查了它们与吸收标志物 CTX-I 的相关性。健康男性的血清 TRAP 5a 和 5b 浓度分别为 4.4±0.6ng/ml 和 1.3±0.2ng/ml,它们彼此中度相关,表明在健康条件下它们的分泌是偶联的。血清 TRAP 5a 和 5b 与 CTX-I 之间也存在相关性,表明两种 TRAP 同工酶都与破骨细胞数量有关。在塑料/骨上的破骨细胞分化过程中,M-CSF/RANKL 刺激的 CD14+PBMCs 的培养基/裂解物中主要增加 5b。然而,在后期检测到大量的 5a,表明两种同工酶都从分化的 OC 中分泌。在骨上释放更多的 TRAP 5b 表明与破骨细胞的吸收活性有关,并且 TRAP 5b/5a 比值的峰值与快速 CTX-I 释放相吻合。在 M-CSF+RANKL 刺激的 CD14+PBMCs 培养结束时,TRAP 5a 和 5b 蛋白与 CTX-I 的分泌之间存在相关性。不仅 5b,而且 5a 与血清和破骨细胞培养物中的胶原降解相关,表明 TRAP 5a 的相当一部分来源于破骨细胞,可能反映了骨吸收和骨重塑过程中一个迄今未被发现的调节机制。